Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

3.35
-0.1100-3.18%
Post-market: 3.33-0.0200-0.60%19:58 EST
Volume:3.92M
Turnover:13.36M
Market Cap:1.00B
PE:-5.81
High:3.60
Open:3.46
Low:3.32
Close:3.46
52wk High:6.52
52wk Low:1.89
Shares:299.34M
Float Shares:202.75M
Volume Ratio:1.41
T/O Rate:1.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5768
EPS(LYR):-0.5533
ROE:-16.81%
ROA:-10.43%
PB:1.04
PE(LYR):-6.05

Loading ...

AbCellera to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 09

Assessing AbCellera Biologics (ABCL) Valuation as It Shifts Toward Proprietary Clinical Assets and Phase 1 Trials

Simply Wall St.
·
Dec 06

Director John S. Montalbano Reports Acquisition of AbCellera Biologics Common Shares

Reuters
·
Nov 27

Assessing AbCellera Biologics (NasdaqGS:ABCL) Valuation After New Facility Launch and Pipeline Progress

Simply Wall St.
·
Nov 26

Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics

TIPRANKS
·
Nov 20

Prelude Therapeutics reports third quarter net loss of $19.7 million

Reuters
·
Nov 12

Stock Track | AbCellera Biologics Plunges 7.20% Following Board Reshuffle and Q3 Earnings Call

Stock Track
·
Nov 11

AbCellera Biologics’ Earnings Call: Key Insights

TIPRANKS
·
Nov 11

Stock Track | AbCellera Biologics Soars 7.03% on Board Appointment and Clinical Progress

Stock Track
·
Nov 11

AbCellera Appoints Stephen Quake to Board as Andrew Lo Resigns

Reuters
·
Nov 10

Abcellera Appoints DR. Stephen Quake to Its Board of Directors

THOMSON REUTERS
·
Nov 10

Stock Track | AbCellera Biologics Soars 5.88% Pre-market on Clinical Progress and Potential Undervaluation

Stock Track
·
Nov 10

Stock Track | AbCellera Biologics Soars 5.88% Pre-market on Clinical Progress and Undervaluation

Stock Track
·
Nov 10

AbCellera Biologics (NasdaqGS:ABCL): How Does the Latest Clinical Progress Impact Its Valuation?

Simply Wall St.
·
Nov 10

Stock Track | AbCellera Biologics Plummets 20.31% on Wider Q3 Loss and Analyst Downgrade

Stock Track
·
Nov 07

Abcellera Biologics Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $4 From $5

THOMSON REUTERS
·
Nov 07

Leerink Downgrades AbCellera Biologics to Market Perform From Outperform, Adjusts Price Target to $4 From $5

MT Newswires Live
·
Nov 07

Stock Track | AbCellera Biologics Plunges 9% Pre-market After Wider-Than-Expected Q3 Loss

Stock Track
·
Nov 07

Stock Track | AbCellera Biologics Surges 5.74% After Q3 Revenue Smashes Estimates

Stock Track
·
Nov 07

AbCellera Biologics Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 07